Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05691309 · ClinicalTrials.gov registry record
Optimizing Vancomycin Therapy in Children
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 29
- Enrollment target
NCT05691309: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT05691309 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05691309 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
Study Summary
The purpose of Opt Vanc is to evaluate the feasibility of Bayesian dose adaptation, based on a previously-developed population pharmacokinetic (PK) model and a single optimally timed PK sample, to predict vancomycin area under the curve (AUC) in critically ill children.
Primary Outcome
This 24-hour vancomycin area under the curve (AUC) will be estimated using Bayesian estimation based on the population pharmacokinetic (PK) model, a subject's measured covariates and the optimally timed vancomycin concentration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2023-11-22 |
What the finished NCT05691309 record still lists
NCT05691309 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05691309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05691309 about?
NCT05691309 is a clinical study titled "Optimizing Vancomycin Therapy in Children". The purpose of Opt Vanc is to evaluate the feasibility of Bayesian dose adaptation, based on a previously-developed population pharmacokinetic (PK) model and a single optimally timed PK sample, to predict vancomycin area under the curve (AUC) in critically ill children.
What is the current status of trial NCT05691309?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2022-12-12. Estimated completion is 2023-11-22.
Who is sponsoring clinical trial NCT05691309?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI